GlassScriptPhysician profile
Chelsa Boswell
NPI 1841561974
$6,657.63
in general payments reported to CMS, 2019-2025
44 companies · $219 in 2025
The $219 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,046 · 2022: $2,495 · 2023: $1,426 · 2024: $472 · 2025: $219.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,116.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $837.90 | 2021-2024 | Rybelsus, Ozempic, Wegovy |
| Preventric Diagnostics, INC. | $676.22 | 2022 | |
| Abbvie INC. | $541.16 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $426.89 | 2021-2024 | Verquvo, Belsomra, Steglatro |
| E.R. Squibb & Sons, L.L.C. | $344.71 | 2022-2023 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $299.61 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $268.54 | 2021-2025 | Jardiance |
| Amgen INC. | $260.36 | 2021-2022 | |
| Amarin Pharma, INC. | $233.55 | 2021 | |
| Lilly USA, LLC | $214.27 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Eisai INC. | $196.64 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $196.36 | 2021-2023 | Spravato, Xarelto |
| Astrazeneca Pharmaceuticals LP | $192.22 | 2021-2025 | Farxiga, Airsupra |
| Pfizer INC. | $157.13 | 2021-2023 | |
| Sanofi-Aventis U.S. LLC | $141.24 | 2021-2022 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chelsa Boswell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.